1. Home
  2. TIC vs ATAI Comparison

TIC vs ATAI Comparison

Compare TIC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acuren Corporation

TIC

Acuren Corporation

HOLD

Current Price

$8.21

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$5.08

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIC
ATAI
Founded
1991
2018
Country
United States
United States
Employees
12760
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
TIC
ATAI
Price
$8.21
$5.08
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$11.20
$15.88
AVG Volume (30 Days)
1.8M
5.6M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,089,000.00
Revenue This Year
$44.09
N/A
Revenue Next Year
$4.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1227.60
52 Week Low
$6.36
$2.16
52 Week High
$14.94
$6.73

Technical Indicators

Market Signals
Indicator
TIC
ATAI
Relative Strength Index (RSI) 47.22 70.85
Support Level $7.80 $4.96
Resistance Level $9.01 $5.51
Average True Range (ATR) 0.39 0.33
MACD 0.00 0.09
Stochastic Oscillator 37.57 88.36

Price Performance

Historical Comparison
TIC
ATAI

About TIC Acuren Corporation

TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Share on Social Networks: